IMATIFLOW 400

Description

Imatinib 400mg IMATIFLOW 400 is a prescription medicine that contains Imatinib 400mg, a targeted cancer therapy widely used in the treatment of certain types of blood cancers and gastrointestinal tumors. Belonging to the class of tyrosine kinase inhibitors (TKIs), Imatinib works by blocking specific abnormal proteins responsible for uncontrolled cancer cell growth. It is most commonly prescribed for conditions like Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Gastrointestinal Stromal Tumors (GISTs). By selectively targeting cancer-causing proteins, IMATIFLOW 400 helps control disease progression, improves survival rates, and enhances the quality of life for patients. Composition and Mechanism of Action Active Ingredient: Imatinib Mesylate equivalent to Imatinib 400mg (IP) How it Works: Imatinib is a protein-tyrosine kinase inhibitor. It blocks the activity of abnormal tyrosine kinases (such as BCR-ABL, c-KIT, and PDGFR), which drive the growth and division of cancer cells. By inhibiting these enzymes, Imatinib prevents cancer cells from multiplying and promotes their destruction, while sparing normal healthy cells. This targeted mechanism makes IMATIFLOW 400 more effective and generally better tolerated compared to traditional chemotherapy. Key Benefits Chronic Myeloid Leukemia (CML): First-line therapy to control abnormal white blood cell growth. Acute Lymphoblastic Leukemia (ALL): Effective in Philadelphia chromosome-positive (Ph+) ALL cases. Gastrointestinal Stromal Tumors (GISTs): Inhibits tumor progression by blocking c-KIT mutations. Other Cancers: Also prescribed for dermatofibrosarcoma protuberans (DFSP) and hypereosinophilic syndrome (HES). Improved Survival Outcomes: Proven to increase long-term remission rates in leukemia patients. Oral Convenience: Tablet format ensures easy administration and better patient compliance. Indications IMATIFLOW 400 is prescribed for: Chronic Myeloid Leukemia (CML) – all phases (chronic, accelerated, blast crisis) Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Gastrointestinal Stromal Tumors (GISTs) Myelodysplastic/Myeloproliferative diseases (MDS/MPD) Hypereosinophilic Syndrome (HES) and Chronic Eosinophilic Leukemia (CEL) Dermatofibrosarcoma Protuberans (DFSP) Dosage and Administration Typical Adult Dose: 400mg once daily with food and a large glass of water. Higher Dose: In some cases, doctors may prescribe 600–800mg daily in divided doses depending on the condition. Route: Oral – swallow the tablet whole, do not crush or chew. Important Notes: Take with meals to reduce gastrointestinal irritation. Dosage must be strictly as directed by the oncologist. Regular monitoring of blood counts and organ function is essential during therapy. Safety Information Contraindications: Known hypersensitivity to Imatinib or its excipients Pregnant or breastfeeding women (unless specifically recommended by a doctor) Precautions: Regular liver, kidney, and blood count monitoring is required. Use effective contraception during therapy. Avoid grapefruit or grapefruit juice (may interfere with metabolism of the drug). Possible Side Effects: Nausea, vomiting, abdominal pain Swelling (edema) around eyes or ankles Muscle cramps, joint pain, fatigue Skin rashes or mild itching In rare cases: liver dysfunction, fluid retention, or bleeding disorders Patients should immediately report symptoms like unexplained bleeding, jaundice, or breathing difficulties. Conclusion IMATIFLOW 400 (Imatinib IP 400mg Tablets) is a breakthrough targeted therapy in oncology, designed to treat blood cancers and solid tumors driven by abnormal tyrosine kinase activity. With its precision action, favorable safety profile, and proven effectiveness, it has become a cornerstone treatment for CML, ALL, GISTs, and related conditions. Under proper medical supervision, IMATIFLOW 400 provides patients with renewed hope, longer remission, and a significantly improved quality of life.